Rangering i aksjer
#13253
SD BioSensor Inc., a global leader in in-vitro diagnostics, delivers advanced... SD BioSensor Inc., a global leader in in-vitro diagnostics, delivers advanced point-of-care testing solutions from its base in South Korea. The company's diverse product portfolio features the STANDARD Q rapid diagnostic platform, offering quick results for various parameters including COVID-19. For laboratory settings, they provide the STANDARD F, a multi-parametric, random-access fluorescence immunoassay system, and the STANDARD E, an ELISA-based solution ideal for extensive screening programs. Their STANDARD M system brings molecular diagnostics closer to the patient, comprising analyzers, assay menus, qPCR reagents, and nucleic acid extraction kits. Furthermore, the procell Dx range focuses on diagnosing infectious diseases such as tuberculosis and SARS-CoV-2, alongside assessing immune status through interferon-gamma release assays. Blood glucose meters also form part of their offerings. Founded in 2010, SD BioSensor is headquartered in Suwon.
Handel SD BioSensor, Inc (137310)
Pris 137310 pris med markedsverdi på B
Markedsverdi av SD BioSensor, Inc(137310)
Markedsverdi: $506.22M
Per August 2026 har SD BioSensor, Inc en markedsverdi på $506.22M. Dette gjør SD BioSensor, Inc til det 13253rd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for SD BioSensor, Inc fra 2021 til 2026
137310 sammenlignet med topp 5 mest populære stocks
| Pris på 137310 |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.285T
|
+1,043,913.91%
|
|
|
|
|
$4.657T
|
+919,941.80%
|
|
|
|
|
$4.052T
|
+800,423.31%
|
|
|
|
|
$3.783T
|
+747,183.38%
|
|
|
|
|
$2.812T
|
+555,305.81%
|
